Connect your AI

Ginkgo Bioworks DNA Other Investing

Other Investing at other companies

Maravai LifeSciences Holdings, Inc.MRVI

$0-100%

DanaherDHR

-$8M-700%

Other financials

Income statement

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForProceedsFromOtherInvestingActivities.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's other investing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ginkgo Bioworks's other investing?: Ginkgo Bioworks (DNA) reported other investing of -$48K in Q1 2026.
How has Ginkgo Bioworks's other investing changed year-over-year?: Ginkgo Bioworks's other investing increased by 60.0% year-over-year, from -$120K to -$48K.
What does other investing mean?: Miscellaneous investing cash flows not classified in specific line items.